ArticleBMC endocrine disorders2025
Hemoglobin glycation index can be used as a predictor of diabetes mellitus and prediabetes: a cohort study.
Article in BMC endocrine disorders, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundDiabetes mellitus (DM) is a significant global public health concern, with prediabetes serving as a critical stage between normoglycemia and DM. Without intervention, individuals with prediabetes face an increased risk of developing DM, underscoring the need for effective preventive measures. The Hemoglobin Glycation Index (HGI)-which measures the discrepancy between actual and predicted glycated hemoglobin (HbA1c) levels-has shown promise in predicting the onset of both microvascular and macrovascular complications associated with DM. However, its potential role in assessing the risk of developing DM or prediabetes remains to be fully established. This study aims to investigate the predictive capacity of HGI for both DM and prediabetes.
methodThis retrospective cohort study utilized data from the China Health and Retirement Longitudinal Study (CHARLS), involving participants aged 45 years and older who were assessed in 2011 and followed up in 2015. Univariate and multivariate logistic regression models were employed to analyze the relationship between HGI and the incidence of prediabetes and DM. Dose-response analyses were conducted using restricted cubic splines, and subgroup analyses were performed based on various demographic and health-related factors.
resultsAmong 3,963 participants, 187 individuals (4.72%) developed prediabetes within four years, and 107 individuals (2.70%) developed DM. HGI was independently associated with an increased risk of developing both DM and prediabetes, with adjusted odds ratios of 1.61 (95% confidence interval [CI]: 1.19-2.16, p = 0.001) and 2.03 (95% CI: 1.40-2.94, p < 0.001), respectively. A linear relationship was observed between HGI and both DM and prediabetes. An interaction effect was identified between age and HGI; specifically, the association between higher HGI and incident DM was more pronounced in individuals aged 45 to 60 years. Among this age group, the OR was 3.93 (95% CI: 2.19-7.05, p < 0.001).
conclusionHGI is identified as an independent risk factor for both DM and prediabetes, demonstrating its utility in predicting the likelihood of their development, particularly within the population aged 45 to 60. These findings highlight the potential of HGI as a valuable biomarker for the early identification of DM risk, thereby facilitating the formulation of targeted intervention strategies.
trial registrationNot applicable.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.